Full Text View
Tabular View
No Study Results Posted
Related Studies
Antiglutamate Anticonvulsants in the Treatment of Alcohol Withdrawal Syndrome
This study has been completed.
First Received: October 17, 2005   Last Updated: October 17, 2006   History of Changes
Sponsor: St. Petersburg State Pavlov Medical University
Information provided by: St. Petersburg State Pavlov Medical University
ClinicalTrials.gov Identifier: NCT00241995
  Purpose

The study is aimed to evaluate the efficacy of antiglutamate anticonvulsants (topiramate, lamotrigine, and memantine) in the treatment of alcohol withdrawal syndrome


Condition Intervention
Topiramate
Lamotrigine
Memnatine
Diazepam
Placebo
Drug: Anticonvulsants

Study Type: Interventional
Study Design: Treatment, Randomized, Single Blind, Placebo Control, Parallel Assignment, Efficacy Study
  Eligibility

Ages Eligible for Study:   20 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Alcohol dependence Alcohol withdrawal syndrome

Exclusion Criteria:

Drug dependence Major psychiatric diagnoses Severe somatic illness

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00241995

Sponsors and Collaborators
St. Petersburg State Pavlov Medical University
Investigators
Principal Investigator: Evgeny M Krupitsky, MD, PhD St. Petersburg State Pavlov Medical University
  More Information

No publications provided

Study ID Numbers: RCT-RCT_LOND_GAT_AWS_2003
Study First Received: October 17, 2005
Last Updated: October 17, 2006
ClinicalTrials.gov Identifier: NCT00241995     History of Changes
Health Authority: Russia: Ministry of Health and Social Development of the Russian Federation

Additional relevant MeSH terms:
Therapeutic Uses
Central Nervous System Agents
Pharmacologic Actions
Anticonvulsants

ClinicalTrials.gov processed this record on February 04, 2010